Literature DB >> 30773269

Hypertensive pregnancy disorders increase the risk of maternal cardiovascular disease after adjustment for cardiovascular risk factors.

Hilde Kristin Refvik Riise1, Gerhard Sulo2, Grethe S Tell3, Jannicke Igland4, Grace Egeland5, Ottar Nygard6, Randi Selmer7, Ann-Charlotte Iversen8, Anne Kjersti Daltveit9.   

Abstract

BACKGROUND AND AIM: Hypertensive pregnancy disorders are associated with subsequent cardiovascular disease (CVD), but the extent to which this association is explained by shared risk factors is unknown. We aimed to evaluate whether hypertensive pregnancy disorder in first pregnancy is associated with increased subsequent risk of maternal CVD after adjustment for established CVD risk factors measured after pregnancy. METHODS AND
RESULTS: A total of 20,075 women with a first delivery registered in the Medical Birth Registry of Norway (1980-2003) participated in Cohort of Norway (CONOR) health surveys a mean (standard deviation) of 10.7 (5.5) years after delivery. They were then followed (median 11.4 years) for an incident fatal or non-fatal CVD event through linkage to the Cardiovascular Disease in Norway (CVDNOR) database and the Norwegian Cause of Death Registry. Hypertensive pregnancy disorders were associated with an increased risk of CVD [Hazard ratio (HR) 2.3; 95% confidence interval (CI) 1.9-2.8], which remained significant after adjustment for established CVD risk factors including body mass index, smoking, hypertension, diabetes, serum glucose and lipid levels (HR 1.5; 95% CI 1.2-1.8). The population attributable fraction of CVD due to hypertensive pregnancy disorder was 4.3% (95% CI 1.9-6.6) after multivariable adjustment.
CONCLUSION: The association between hypertensive pregnancy disorders and CVD risk was mediated in part by related CVD risk factors measured 10 years following delivery. These results underline the importance of post-pregnancy follow-up of women with hypertensive pregnancy disorders focusing on modifiable, lifestyle related risk factors to prevent future CVD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Cardiovascular risk factors; Cohort study; Hypertensive pregnancy disorder; Pregnancy; Women's cardiovascular health

Mesh:

Year:  2019        PMID: 30773269     DOI: 10.1016/j.ijcard.2019.01.097

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  16 in total

Review 1.  The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women.

Authors:  Priya M Freaney; Sadiya S Khan; Donald M Lloyd-Jones; Neil J Stone
Journal:  Curr Atheroscler Rep       Date:  2020-07-16       Impact factor: 5.113

2.  Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.

Authors:  Angela H E M Maas; Giuseppe Rosano; Renata Cifkova; Alaide Chieffo; Dorenda van Dijken; Haitham Hamoda; Vijay Kunadian; Ellen Laan; Irene Lambrinoudaki; Kate Maclaran; Nick Panay; John C Stevenson; Mick van Trotsenburg; Peter Collins
Journal:  Eur Heart J       Date:  2021-03-07       Impact factor: 29.983

3.  Does Adding Adverse Pregnancy Outcomes Improve the Framingham Cardiovascular Risk Score in Women? Data from the Tehran Lipid and Glucose Study.

Authors:  Marzieh Saei Ghare Naz; Ali Sheidaei; Ali Aflatounian; Fereidoun Azizi; Fahimeh Ramezani Tehrani
Journal:  J Am Heart Assoc       Date:  2022-01-11       Impact factor: 6.106

4.  The Impact of Subclinical Hypothyroidism on Adverse Perinatal Outcomes and the Role of Thyroid Screening in Pregnancy.

Authors:  Mei-Qin Wu; Jin Liu; Ya-Qian Wang; Ying Yang; Chong-Huai Yan; Jing Hua
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-06       Impact factor: 5.555

Review 5.  Hypertensive Disorders of Pregnancy and Future Cardiovascular Health.

Authors:  Karen Melchiorre; Basky Thilaganathan; Veronica Giorgione; Anna Ridder; Alessia Memmo; Asma Khalil
Journal:  Front Cardiovasc Med       Date:  2020-04-15

6.  Second trimester maternal serum D-dimer combined with alpha-fetoprotein and free β-subunit of human chorionic gonadotropin predict hypertensive disorders of pregnancy: a systematic review and retrospective case-control study.

Authors:  Yiming Chen; Yijie Chen; Xue Wang; Xuelian Chu; Wenwen Ning; Linyuan Gu; Liyao Li; Zhen Xie; Caihe Wen
Journal:  J Transl Med       Date:  2021-03-02       Impact factor: 5.531

7.  Future Cardiovascular Disease Risk for Women With Gestational Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Charmaine Chu Wen Lo; Andre C Q Lo; Shu Hui Leow; Grace Fisher; Beth Corker; Olivia Batho; Bethan Morris; Monika Chowaniec; Catherine J Vladutiu; Abigail Fraser; Clare Oliver-Williams
Journal:  J Am Heart Assoc       Date:  2020-06-24       Impact factor: 5.501

Review 8.  Use of Race, Ethnicity, and National Origin in Studies Assessing Cardiovascular Risk in Women With a History of Hypertensive Disorders of Pregnancy.

Authors:  Amy Johnston; Victrine Tseung; Sonia R Dancey; Sarah M Visintini; Thais Coutinho; Jodi D Edwards
Journal:  CJC Open       Date:  2021-08-20

9.  Maternal Coronary Heart Disease, Stroke, and Mortality Within 1, 3, and 5 Years of Delivery Among Women With Hypertensive Disorders of Pregnancy and Pre-Pregnancy Hypertension.

Authors:  Angela M Malek; Dulaney A Wilson; Tanya N Turan; Julio Mateus; Daniel T Lackland; Kelly J Hunt
Journal:  J Am Heart Assoc       Date:  2021-02-23       Impact factor: 5.501

10.  An observational claims data analysis on the risk of maternal chronic kidney disease after preterm delivery and preeclampsia.

Authors:  Maren Goetz; Mitho Müller; Raphael Gutsfeld; Tjeerd Dijkstra; Kathrin Hassdenteufel; Sara Yvonne Brucker; Armin Bauer; Stefanie Joos; Miriam Giovanna Colombo; Sabine Hawighorst-Knapstein; Ariane Chaudhuri; Gudula Kirtschig; Frauke Saalmann; Stephanie Wallwiener
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.